Autoimmune Profile Updates
Test in Focus
Mayo Clinic Laboratories is adjusting a number of its autoimmune profiles by removing certain antibodies from those profiles. In this "Test in Focus" episode of the "Answers From the Lab" podcast, Andrew McKeon, M.B., B.Ch., M.D., explains the rationale behind the test updates.
"These are not radical changes by any means. This is something that's been evolving over time," Dr. McKeon says. "We've collected data to drill down on the significance of test results in different phenotypes. Based on that, we're recalibrating our profiles to make sure what's in there is of the highest clinical utility for our providers." Listen to learn more from Dr. McKeon about the specifics of the autoimmune profile updates, and how the changes will streamline testing and enhance test interpretation.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Sean Pittock, M.D., explains how Mayo Clinic Laboratories' novel Ma2 test aids diagnosis of autoimmune neurology disorders that are often caused by underlying cancer. Rapid diagnosis is key to preventing significant disability and disease.
In this test-specific episode of the "Answers From the Lab" podcast, Rong He, M.D., explains how Mayo Clinic Laboratories' IDHQ test improves upon next generation sequencing for assessing AML treatment options.
In this test-specific episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, and Bjorn Oskarsson, M.D., a neurologist at Mayo Clinic’s Florida campus, discuss how the neurofilament light chain test available through Mayo Clinic Laboratories helps physicians diagnose neurological disease and assess neuronal damage.